Inhibition experiments with synthetic PPARγ ligands suggested a PPARγ-dependent and independent effect of LPC on DC maturation. Therefore, the relative amount of oxidized fatty acids and LPC influences the immunological functions of oxLDL on DC, in part by regulating the PPAR pathway. By sensing the biochemical composition of lipoprotein particles, the innate immune system may thus identify various endogenous signals that influence the immune response during the acute phase reaction. The therapeutic emulsion Intralipid also blocks LPC action on PPAR activity and DC maturation. Intralipid may thus be an alternative therapeutic strategy for some chronic inflammatory diseases.
Introduction
The acute phase response (APR) 3 to tissue injury is a series of reaction invoked by the liver to prevent tissue damage, favor pathogen clearance and activate the repair processes that are necessary to restore normal functions (1) . APR is a rapid and transient deviation from homeostasis and is part of the systemic inflammatory arsenal of innate immunity. One of the consequences of APR is an oxidative modification of low density lipoprotein (LDL), the main transporter of cholesterol in humans (2, 3) . During homeostasis, LDL is protected from oxidative modification by lipoprotein-associated enzymes which prevent the accumulation of biologically active modified lipids (4) . During APR, acute phase reactants transiently integrate lipoprotein and modify LDL-associated enzymes activity which in turn lose their ability to control LDL oxidation (5) . In recent studies, we showed that oxidized LDL (oxLDL) promotes mature dendritic cell (DC) generation from monocytes, therefore linking the nonspecific acute phase response to adaptive immunity (6) . Mature DC generation induced by oxLDL was inhibited by native LDL and lipid emulsions. Based on these observations, it was hypothesized that the innate immune system could modulate the commitment of adaptive immunity to the host defense strategy by sensing the balance between native and oxidized LDL and the production of oxidized phospholipids.
As our understanding of LDL oxidation has evolved, it has become clear that oxLDL can act both to favor and inhibit inflammation depending on its own biochemical composition and cell type studied. Oxidation of LDL is a complex reaction generating various lipid mediators and the functional dualism of oxLDL is likely to reflect the relative level of these mediators in the particle. Among these lipid mediators, lysophosphatidylcholine (LPC) and oxidized fatty acids are of special interest because they display opposite effects on inflammation. High concentration of LPC appear to confer proinflammatory properties to oxLDL and a number of 3 
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LPC represents 1-5 % of the total phosphatidylcholine content of native LDL and its concentration is raised to 40-50 % upon LDL oxidation (10) . LPC content is also increased in circulating LDL after LPS treatment (11) . LPC is generated by oxidation and fragmentation of the polyunsaturated sn-2 fatty acyl residues of phosphatidylcholine followed by hydrolysis of the shortened fatty acyl residues (12) . In previous reports, we have shown that the ability of oxLDL to promote mature DC generation was mediated by LPC through a G protein-coupled receptor. This function was modulated by native LDL and lipid nanoemulsion including the therapeutic emulsion Intralipid (13) .
Other classes of oxidized lipids identified in oxLDL display anti-inflammatory properties.
These lipids are peroxidation products of linoleic acid and arachidonic acid, the most abundant fatty acids in human LDL. LDL oxidation transforms linoleic acid and arachidonic acid to hydroperoxy derivatives which are converted to hydroxyoctadecadienoic acid (HODE) and hydroxyeicosatetraenoic acid (HETE) respectively (14) . HODE and HETE are also products of lipoxygenases that can oxygenate free polyunsaturated fatty acids and phospholipids present in native LDL and in biomembranes (15) . Under specific conditions, 9-HODE and 13-HODE can account for more than 60 % of all lipid peroxidation products found in oxLDL (14) . 9-, 13-HODE and 11-, 15-HETE are activating ligands for the nuclear peroxisome proliferator-activated receptor γ (PPARγ) (16, 17) . Ligands of PPARγ can interfere with monocyte and macrophage functions by inhibiting the production of inflammatory cytokines (18, 19) . Moreover some ligands can have anti-inflammatory effects that are independent of PPARγ (20).
PPARs are important therapeutic targets in metabolic disorders (21, 22). The three PPARs isoforms (α, γ and δ) bind to the peroxisome proliferator response element (PPRE) as a heterodimer with the 9-cis retinoid receptor (RXR) and exhibit various functions relevant to 
Monocyte-derived dendritic cells
Monocytes were isolated from human peripheral blood as described previously (6 
Treatment of differentiating monocytes
We have previously observed that direct generation of mature DC from differentiating monocytes was best achieved when oxLDL was added at day 5 of differentiation for 24h in lipoprotein deficient serum to prevent inhibition by native LDL (6) . Differentiating monocytes were thus treated at day 5 as indicated and incubated for 24 hours at 37°C. When mentioned, PPARγ agonists 9-HODE or 13-HODE (25 µg/ml), 11-HETE or 15-HETE (12.5 µg/ml) or Ciglitizone (50 µM) were added 15 min prior to oxLDL (10 µg/ml) or LPC (40 µM). Intralipid 20 % (50 µg/ml phospholipids as described in (13)) was added concomitantly with LPC (40 µM). At the end of the differentiation (day 6), cell viability was superior to 90 %.
Phenotype
Phenotype was analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, Franklin
Lakes, NJ, USA) using FITC-conjugated anti-CD14, -HLA-DR, -CD80 and PE-conjugated anti-CD1a, -CD86, -CD40 all from Beckman Coulter. 
Mixed Lymphocyte Reaction
Naïve T lymphocytes were isolated from human peripheral blood as described (6 
Results

OxLDL-induced DC functional maturation is inhibited by 9-HODE
The presence of oxLDL during monocyte differentiation yielded phenotypically and functionally mature DC (6). This effect is mediated by LPC generated during LDL oxidation (13) . In addition to pro-inflammatory modified phospholipids, LDL oxidation also generates anti-inflammatory oxidized fatty acids like 9-HODE from linoleic acid. As oxLDL function is likely to depend on its relative content in modified phospholipids and fatty acids, we first asked whether an excess of HODE could affect the process of DC maturation induced by oxLDL. Monocytes differentiated to immature DC in GM-CSF and IL-4 in the absence of oxLDL expressed high levels of CD1a but no CD14, intermediate levels of HLA-DR and CD40 and were negative or low for CD86 and CD80 (Fig. 1A) . Phenotype of 9-HODEtreated cells (25 µg/ml) was identical to control cells (data not shown). Cells treated with oxLDL (10 µg/ml) up-regulated HLA-DR, CD80, CD86 and CD40 but CD1a remained high as previously described (6) . Addition of 9-HODE (25 µg/ml) together with oxLDL (10 µg/ml) did not prevent oxLDL-induced up-regulation of HLA-DR, CD86, CD80 and slightly reduced CD40 expression.
The ability of DC generated in the presence of oxLDL and 9-HODE to stimulate allogeneic T cells was further analyzed. As expected oxLDL-treated cells stimulated IFNγ secretion by allogeneic T cells while untreated (immature DC) or 9-HODE-treated cells did not (Fig. 1B) .
However, when DC were generated in the presence of both oxLDL and 9-HODE, allogeneic T cells were not stimulated to secrete IFNγ. Therefore, in the presence of additional 9-HODE, oxLDL induced phenotypical but not functional maturation of DC.
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Effect of oxLDL on DC is inhibited by natural and synthetic PPARγ ligands
We then asked whether the functional effect of 9-HODE could be extended to other oxidized fatty acids generated during LDL oxidation. 13-HODE is another major oxidized metabolite of linoleic acid identified in oxLDL. Figure 2A shows that cotreatment with oxLDL and 13-HODE resulted in the generation of DC that do not stimulate IFNγ secretion by allogeneic T cells. The same results were obtained with the oxidized metabolites of arachidonic acid, 11-HETE and 15-HETE (Fig. 2B, C) . Therefore, 9-HODE, 13-HODE, 11-HETE and 15-HETE inhibited the capacity of oxLDL to generate activating DC from differentiating monocytes. As all these lipids are ligands for PPARγ, inhibition of oxLDL-induced functional maturation of DC was tested using the specific synthetic agonist of PPARγ ciglitizone. As shown in Figure   2D , DC generated in the presence of oxLDL and ciglitizone lost their ability to stimulate IFNγ secretion by allogeneic T cells. As observed for 9-HODE, neither 13-HODE, HETE nor ciglitizone inhibited oxLDL-induced up-regulation of HLA-DR and costimulatory molecules except for a slight reduction of CD40 induction (data not shown). Overall these data suggest that PPARγ ligands can modulate the immunological function of oxLDL, some of these ligands being generated during the process of LDL oxidation in the form of oxidized fatty acids.
PPARγ agonists inhibit functional maturation of LPC-treated DC
LPC is a major component of oxidized LDL that can activate various cell types and is implicated in many aspects of the inflammatory response. In a recent study we showed that LPC mimicked oxLDL in that it was able to generate mature DC from differentiating monocytes (13) . Experiments were thus conducted to test whether activation of PPARγ with ciglitizone could inhibit LPC action on DC as it did for oxLDL. As previously reported (13) 
LPC inhibits the PPARγ pathway
The effect of LPC on the PPAR pathway was studied. EMSA were then performed with nuclear extracts of cells treated with the PPARγ ligand ciglitizone. This treatment resulted in an increase of complex I in nuclear extracts while complex II was unaffected, strongly suggesting that complex I represents activated PPARγ (Fig. 4B, lane 3) . Inhibition of LPC by ciglitizone can be visualized at the level of these complexes. Indeed, while complex I disappeared upon LPC treatment, it is not affected when cells are treated concomitantly with LPC and ciglitizone (Fig. 4B, lane 4) . In addition, complex II is strongly induced by LPC but this induction is inhibited by ciglitizone.
Further characterization of these complexes was performed by supershift and blotting experiments. The addition of a PPARγ-specific anti-serum supershifted the complex I in ciglitizone-treated extracts, confirming the presence of PPARγ in this complex (Fig. 4C) .
Anti-PPARα, anti-COUP-TF or anti-PPARδ antibodies had no effect on the mobility shift pattern of complex I (data not shown).
To further characterize complex I, nuclear extracts gel shift from control and LPC-treated cells (Fig. 5A ) were subjected to membrane blotting. Immunoblotting with a PPARγ antibody confirmed the presence of PPARγ in complex I and its absence from complex II (Fig 5B) .
After total stripping, incubation of the same membrane with a RXRα specific antibody revealed that complex I but not complex II also contained RXRα. These experiments 
Intralipid modulates DNA binding activity of PPARs
We have shown previously that Intralipid can block the ability of LPC to induce functional maturation of DC (13) . This ability to inhibit LPC-induced DC maturation is shared by ciglitizone which was shown above to block LPC action on PPARs. Therefore, we analyzed the effect of Intralipid on DNA-binding activities of the same transcription factors. In the presence of Intralipid, the effect of LPC on the DNA-binding activity of complex I and complex II was inhibited (Fig 6A) . To further analyze the mechanism of action of Intralipid, cells were treated with Intralipid alone (50 µg/ml of phospholipids) for 1h to 24h and nuclear proteins were subjected to EMSA. Treatment with Intralipid resulted in a time dependent activation of complex I and a progressive decrease of complex II activity (Fig. 6B) . Therefore, DNA-binding activity of PPARγ/RXRα was stimulated by Intralipid while that of complex II was inhibited, conferring a direct role for Intralipid in gene transcription. Addition of these lipids together with oxLDL had no significant effect on the induction of presentation or costimulatory molecules, except for CD40. These DC were unable to stimulate the secretion of IFNγ by allogeneic T cells. Our data suggest that the relative production of LPC and HODE/HETE during LDL oxidation may determine the immunological properties of oxLDL.
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Whether this is due to the lack of CD40 or CD80 induction remains to be determined. In addition, no Th2 bias was observed under these experimental conditions as no increase in IL- 
